Serum DNase i activity in systemic lupus erythematosus: Correlation with immunoserological markers, the disease activity and organ involvement

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 5, 2013, Pages 1083-1091

  Skiljevic, Dusan ^a   Jeremic, Ivica ^b   Nikolic, Milos ^a   Andrejevic, Sladjana ^c   Sefik Bukilica, Mirjana ^c   Stojimirovic, Biljana ^a   Bonaci Nikolic, Branka ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b INSTITUTE OF RHEUMATOLOGY   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Antinuclear antibodies; Desoxyribonuclease I; High avidity anti dsDNA antibodies; SLEDAI; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEASE; DEOXYRIBONUCLEASE I; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSOME ANTIBODY;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD DONOR; BLOOD LEVEL; CHROMATIN; CONTROL GROUP; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; DEOXYRIBONUCLEASE I; ENZYME ACTIVATION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84882275072     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0521     Document Type: Article

References (47)

1. Vyse TJ, Kotzin BL. Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol 1998;16:261-92.
2. Tsukumo S, Yasutomo K. DNase I in pathogenesis of systemic lupus erythematosus. Clin Immunol 2004;113:14-8.
3. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-50.
4. Yasutomo K. Pathological lymphocyte activation by defective clearance of self-ligands in systemic lupus erythematosus. Rheumatology (Oxford) 2003;42:214-22.
5. Kyttaris VC, Juang YT, Tsokas G. Immune cells and cytokines in SLE: an update. Curr Opin Rheumatol 2005;17:518-22.
6. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003;56:481-90.
7. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-50.
8. Graham KL, Utz PJ. Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:513-7.
9. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, M ö r ö y T. Features of systemic lupus erythematosus in DNase I 1-deficient mice. Nat Genet 2000;25:177-81.
10. Napirei M, Wulf S, Mannherz HG. Chromatin breakdown during necrosis by serum DNase I 1 and the plasminogen system. Arthritis Rheum 2004;50:1873-83.
11. Mannherz HG, Peitsch MC, Zanotti S, Paddenberg R, Polzar B. A new function for an old enzyme: The role of DNase I in apoptosis. Curr Top Microbiol Immunol 1995;198:161-74.
12. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase- activated DNase I that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391:43-50.
13. Lacks SA. Deoxyribonuclease I in mammalian tissues: specificity of inhibition by actin. J Biol Chem 1981;256:2644-8.
14. Takeshita H, Yasuda T, Nakajima T, Hosomi O, Nakashima Y, Kishi K. Mouse deoxyribonuclease I (DNase I): biochemical and immunological characterization, cDNA structure and tissue distribution. Biochem Mol Biol Int 1997;42:65-75.
15. Chitrabamrung S, Rubin RL, Tan EM. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1981;1:55-60.
16. Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas- Fernandez A, Vilardell-Tarres M. DNase I activity in patients with systemic lupus erythematosus: relationship with epidemio- logical, clinical, immunological and therapeutical features. Lupus 2009;18:418-23.
17. Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas- Fernandez A, Vilardell-Tarres M. DNase I activity in systemic lupus erythematosus patients with and without nephropathy. Rheumatol Int 2010;30:1601-4.
18. Mart í nez Valle F, Balada E, Ordi-Ros J, Vilardell-Tarres M. DNase I and systemic lupus erythematosus. Autoimmun Rev 2008;7:359-63.
19. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, et al. Mutation of DNase I in people with systemic lupus erythematosus. Nat Genet 2001;28:313-4.
20. Sallai K, Nagy E, Derfalvy B, M ü zes G, Gergely P. Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus. Clin Diagn Lab Immunol 2005;12:56-9.
21. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
22. Gladman DD, Iba ñ ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
23. Romero-Díaz J, Vargas-Vóracková F, Kimura-Hayama E, Cort ázar- Ben í tez LF, Gij ó n-Mitre R, Criales S, et al. Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology 2012;51:110-9.
24. Licht R, Dieker JW, Jacobs CW, Tax WJ, Berden JH. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun 2004;22:139-45.
25. Dieker JW, van der Vlag J, Berden JH. Triggers for anti-chromatin autoantibody production in SLE. Lupus 2002;11:856-64.
26. Gaipl US, Sheriff A, Franz S, Munoz LE, Voll RE, Kalden JR, et al. Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol 2006;305:161-76.
27. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-30.
28. Michlewska S, McColl A, Rossi AG, Megson IL, Dransfield I. Clearance of dying cells and autoimmunity. Autoimmunity 2007;40:267-73.
29. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-1.
30. Macanovic M, Lachmann PJ. Measurement of deoxyribonuclease I (DNase I ) in the serum and urine of systemic lupus erythematosus(SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 1997;108:220-6.
31. Hakkim A, F ü rnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010;107:9813-8.
32. Tew MB, Johnson RW, Reveille JD, Tan FK. A molecular analysis of the low serum deoxyribonuclease activity in lupus patients. Arthritis Rheum 2001;44:2446-7.
33. Balada E, Ordi-Ros J, Hernanz S, Villarreal J, Cort é s F, Vilardell-Tarr é s M, et al. DNASE I mutation and systemic lupus erythematosus in a Spanish population: comment on the article by Tew, et al. Arthritis Rheum 2002;46:1974-6; author reply 1976-7.
34. Chakraborty P, Kacem HH, Makni-Karray K, Jarraya F, Hachicha J, Ayadi H. The A/T mutation in exon 2 of the DNASE I 1 gene is not present in Tunisian patients with systemic lupus erythematosus or in healthy subjects. Arthritis Rheum 2003;48:3297-8.
35. Simmonds MJ, Heward JM, Kelly MA, Allahabadia A, Foxall H, Gordon C, et al. A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves ' disease: comment on the article by Rood et al. Arthritis Rheum 2002;46:3109-10.
36. Lazarides E, Lindberg U. Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proc Natl Acad Sci USA 1974;71:4742-6.
37. Frost PG, Lachmann PJ. The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol 1968;3:447-55.
38. Yeh TM, Chang HC, Liang CC, Wu JJ, Liu MF. Deoxyribonucleaseinhibitory antibodies in systemic lupus erythematosus. J Biomed Sci 2003;10:544-51.
39. Bartoloni E, Ludovini V, Alunno A, Pistola L, Bistoni O, Crin ò L, et al. Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjögren's syndrome. Lupus 2011;20:928-35.
40. Baranovskii AG, Buneva VN, Nevinsky GA. Human deoxyribonucleases. Biochemistry (Mosc) 2004;69:587-601.
41. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov AG. DNA hydrolyzing autoantibodies. Science 1992;256:665-7.
42. Nevzorova TA, Temnikov DA, Vinter VG. Special features of the DNA-hydrolyzing activity of the antibodies in systemic lupus erythematosus. Biochemistry (Mosc) 2003;68:1300-6.
43. Drosera M, Facchetti F, Landolfo S, Mondini M, Nyberg F, Parodi A, et al. Role of soluble and cell surface molecules in the pathogenesis of autoimmune skin diseases. Clin Exp Rheumatol 2006;24(1 Suppl 40):S7- 13.
44. Hedberg A, Fismen S, Fenton KA, Mortensen ES, Rekvig OP. Deposition of chromatin-IgG complexes in skin of nephritic MRL-lpr/lpr mice is associated with increased local matrix metalloprotease activities. Exp Dermatol 2010;19:e265-74.
45. Lahm A, Suck D. DNase I-induced DNA conformation. 2 A structure of a DNase I-octamer complex. J Mol Biol 1991;222:645-67.
46. Weston SA, Lahm A, Suck D. X-ray structure of the DNase I-d(GGTATACC)2 complex at 2.3 A resolution. J Mol Biol 1992;226:1237-56.
47. Manderson AP, Carlucci F, Lachmann PJ, Lazarus RA, Festenstein RJ, Cook HT, et al. The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R68.